Overview

• US laboratory services provider's Q1 revenue rose 5.8% yr/yr, beating analyst expectations

• Adjusted EPS for Q1 increased 10.6% yr/yr to $4.25

• Company raised full-year 2026 revenue and adjusted EPS guidance

Outlook

• Labcorp raises 2026 full-year enterprise revenue guidance to $14.65-$14.80 bln, up 20 bps at midpoint

• Company sees 2026 adjusted EPS between $17.70 and $18.35, up $0.13 at midpoint

• Labcorp expects Diagnostics Laboratories revenue of $11.43-$11.52 bln and Biopharma Laboratory Services revenue of $3.22-$3.27 bln

Result Drivers

• ORGANIC GROWTH - Labcorp said organic growth was the primary driver of increased adjusted operating income and margin

• DIAGNOSTICS AND CENTRAL LABS MOMENTUM - Co cited continued momentum across Diagnostics and Central Laboratory businesses as supporting robust growth

• STRATEGIC INITIATIVES - Expansion in specialty and companion diagnostics, new collaborations, and investments in technology supported growth

Company press release: ID:nPn8T4RVpa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Revenue	Beat	$3.54 bln	$3.50 bln (14 Analysts)
Q1 Adj EPS from Cont Ops		$4.25

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities & services peer group is "buy"

• Wall Street's median 12-month price target for Labcorp Holdings Inc is $320.00, about 24.4% above its April 29 closing price of $257.14

• The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 14 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.